Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ixekizumab
Drug ID BADD_D01224
Description Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Indications and Usage Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Marketing Status approved; investigational
ATC Code L04AC13
DrugBank ID DB11569
KEGG ID D10071
MeSH ID C549079
PubChem ID Not Available
TTD Drug ID D08NMV
NDC Product Code 0002-1445; 0002-7724; 63419-0536
UNII BTY153760O
Synonyms ixekizumab | Taltz | LY2439821 | LY-2439821
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1143503-69-8
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Conjunctivitis06.04.01.002; 11.01.06.012--
Erythema23.03.06.001---
Hypersensitivity10.01.03.003--
Infection11.01.08.002---
Inflammatory bowel disease07.08.01.016---
Influenza11.05.03.001; 22.07.02.001---
Injection site reaction08.02.03.014; 12.07.03.015--
Nausea07.01.07.001--
Neutropenia01.02.03.004---
Oral candidiasis07.05.07.001; 11.03.03.004---
Pain08.01.08.004--
Psoriasis10.02.01.036; 23.03.14.002---
Rhinitis11.01.13.004; 22.07.03.006--
Thrombocytopenia01.08.01.002---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Tinea infection11.03.08.002; 23.11.03.011---
The 1th Page    1    Total 1 Pages